Community Research and Development Information Service - CORDIS

Abstract

In a prospective study, 200 primary human breast cancer specimens were analysed for epidermal growth factor receptor (EGFR) content by means of a multiple point ligand binding assay, proposed by the EORTC Receptor Study Group to be the standard EGFR assay. In 54% of the tumours the presence of saturable high affinity binding sites for epidermal growth factor could be demonstrated. The median EGFR level was 34 fmol/mg of membrane protein, and the median K(d) 0.50 nmd. Univariate analysis of the EGFR data stratified according to patient age, menopausal status, tumour size, axillary lymph node status, histological tumour type, tumour differentiation grade or the tumours' steroid hormone receptor status, showed EGFR to be positively associated with younger age (P = 0.03), tumour de-differentiation (P = 0.04) and steroid hormone receptor negativity (P less than 0.001). However, no association between EGFR and menopausal status, tumour size, axillary lymph node status or histological tumour type could be demonstrated.

Additional information

Authors: KOENDERS P G, University Hospital Nijmegen, Department of Experimental and Chemical Endocrinology (NL);KIENHUIS C B M, University Hospital Nijmegen, Department of Experimental and Chemical Endocrinology (NL);BENRAAD T J, University Hospital Nijmegen, Department of Experimental and Chemical Endocrinology (NL);FAVERLEY D, University Hospital Nijmegen, Department of Pathology (NL);BEEX L V A M, University Hospital Nijmegen, Department of Medicine (NL);BRUGGINK E D M, Canisius-Wilhelmina Hospital, Department of Surgery, Nijmegen (NL)
Bibliographic Reference: Article: European Journal of Cancer, Vol. 28 (1992) No. 2/3, pp. 693-697
Record Number: 199211043 / Last updated on: 1994-12-02
Category: PUBLICATION
Original language: en
Available languages: en
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top